ReviewNuclear medicine and biology2007
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
Review in Nuclear medicine and biology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 125 citations in OpenAlex.
- High-Yield Room-Temperature ArylACS organic & inorganic Au · 2026Article
- Tellurium-118 as a novel radionuclide for long-term positron emission tomography.Scientific reports · 2026Article
- Uptake and Binding of At-211 Into K- and Cs-Derivatives of Alpha-Zirconium Phosphate Nanoplatelets for Use as a Targeted Alpha Therapy Delivery Platform.Small science · 2026Article
- Novel astatine (European journal of nuclear medicine and molecular imaging · 2025Article
- In vitro and in vivo evaluation of a tetrazine-conjugated poly-L-lysine effector molecule labeled with astatine-211.EJNMMI radiopharmacy and chemistry · 2024Article
- Effective Treatment of SSTR2-Positive Small Cell Lung Cancer UsingMolecular pharmaceutics · 2023Article
- Pretargeted Alpha Therapy of Disseminated Cancer Combining Click Chemistry and Astatine-211.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Efficient Production of the PET RadionuclidePharmaceuticals (Basel, Switzerland) · 2022Article
- Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle EmitterMolecular pharmaceutics · 2022Article
- Production of GMP-Compliant Clinical Amounts of Copper-61 Radiopharmaceuticals from Liquid Targets.Pharmaceuticals (Basel, Switzerland) · 2022Article
- DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.Cancers · 2022Review
- Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?Frontiers in medicine · 2022Review
- Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin.Theranostics · 2022Article
- Covalent core-radiolabeling of polymeric micelles withNanotheranostics · 2022Article
- Article
- A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.Theranostics · 2021Review
- Radiopharmaceutical Chemistry and Drug Development-What's Changed?Seminars in radiation oncology · 2021Review
- Human dosimetry of freeEJNMMI physics · 2020Article
- Construction and Preclinical Evaluation of 211At Labeled Anti-mesothelin Antibodies as Potential Targeted Alpha Therapy Drugs.Journal of radiation research · 2020Article
- Nanoparticles in Targeted Alpha Therapy.Nanomaterials (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
An attractive feature of targeted radionuclide therapy is the ability to select radionuclides and targeting vehicles with characteristics that are best suited for a particular clinical application. One combination that has been receiving increasing attention is the use of monoclonal antibodies (mAbs) specifically reactive to receptors and antigens that are expressed in tumor cells to selectively deliver the alpha-particle-emitting radiohalogen astatine-211 (211At) to malignant cell populations. Promising results have been obtained in preclinical models with multiple 211At-labeled mAbs; however, translation of the concept to the clinic has been slow. Impediments to this process include limited radionuclide availability, the need for suitable radiochemistry methods operant at high activity levels and lack of data concerning the toxicity of alpha-particle emitters in humans. Nonetheless, two clinical trials have been initiated to date with 211At-labeled mAbs, and others are planned for the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.